Versant Ventures related stories
All articles and analysis
VC-backed Imara appoints new CEOCambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.
- Gilde Healthcare and Versant Ventures leads funding round for Lava Therapeutics
Lava Therapeutics, a Dutch biotech company, has raised 16 million euros in funding. Gilde Healthcare and Versant Ventures led the round with participation from MRL Ventures Fund, Lupus Ventures and Biox Biosciences.
- Enterprise Therapeutics raises 29 mln pounds
Enterprise Therapeutics Ltd said April 12 that it raised 29 million pounds ($41 million) in a Series B round co-led by Versant Ventures and Novartis Venture Fund. The syndicate also included new investor Forbion, founding investor Epidarex Capital and existing investor IP Group. Enterprise Therapeutics Ltd is a biopharmaceutical company that is developing therapies for the treatment of respiratory diseases.
- VC-backed Roche Holdings buys Inception 5 program
Roche Holdings, which is backed by Versant Ventures, has acquired the Inception 5 program. No financial terms were disclosed. Inception is focused on regenerative therapies for multiple sclerosis.
- Tempest Therapeutics hauls in $70 mln Series B
San Francisco-based Tempest Therapeutics, a biotechnology company, has closed $70 million in Series B financing. The investors included Versant Ventures, F-Prime Capital Partners, Quan Capital, Lilly Asia Ventures, Foresite Capital and Eight Roads Ventures.
- VC-backed Gritstone Oncology appoints EVP of technical operations
Emeryville, California-based Gritstone Oncology, a personalized cancer immunotherapy company, has named Dr. Jayant Aphale as executive vice president of technical operations. Previously, he was vice president of technical operations at Sarepta Therapeutics. Gritstone Oncology’s backers include Versant Ventures, The Column Group, Clarus Funds, Frazier Healthcare Partners, RedMile, Casdin Capital, Lilly Asia Ventures, Trinitas Capital, GV, Alexandria Venture Investments and Bay City Capital.
- Quentis Therapeutics inks $48 mln Series A
New York City-based Quentis Therapeutics, a biotech company that focuses on treating cancer patients, has raised $48 million in Series A funding. The investors included Versant Ventures, Polaris Partners, AbbVie Ventures, Taiho Pharmaceutical Co. Ltd, Yonghua Capital, Alexandria Venture Investments and New York Ventures, the investment arm of Empire State Development.
- VC-backed Gritstone Oncology recruits Bellemin as EVP of finance and CFO
Emeryville, California-based Gritstone Oncology, a personalized cancer immunotherapy company, has named Jean-Marc Bellemin as executive vice president of finance and chief financial officer. His appointment became effective January 5, 2018. Previously, Bellemin worked at Actelion Pharmaceuticals USA where he served as senior vice president and chief financial officer. Gritstone Oncology's backers include Versant Ventures, The Column Group, Clarus Funds, Frazier Healthcare Partners, RedMile, Casdin Capital, Lilly Asia Ventures, Trinitas Capital, GV, Alexandria Venture Investments and Bay City Capital.
- Pandion Therapeutics snags $58 mln Series A
Cambridge, Massachusetts-based Pandion Therapeutics, a biotech company, has closed $58 million in Series A financing. Polaris Partners, Versant Ventures and Roche Venture Fund led the round with participation from SR One and BioInnovation Capital.